UK-listed Silence Therapeutics plc and privately held Intradigm Corp. agreed to a merger deal that could give the combined firm a competitive edge in the RNAi landscape currently dominated by firms such as Alnylam Pharmaceuticals Inc. and Sirna Therapeutics Inc. (BioWorld Today)